AUTHORS
Yumeng Zhang, MD, Supreet Kaur, MD2, Daniel DeAvila Jr, M.S.3, Celeste Bello, MD4, Leidy Isenalumhe, MD, MS5, Lubomir Sokol, MD, PhD6, Sameh Gaballa, MD7, Bijal Shah, MD, MS8, Javier Pinilla-Ibarz, MD PhD9
AFFILIATIONS
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Background. Patients with CLL who stop a covalent BTK inhibitor (cBTKi) for intolerance are commonly switched within class, and those completing fixed-duration venetoclax may be retreated. Whether either class retains activity in these settings, and how often cBTKi switching is followed by repeat discontinuation for intolerance, remain incompletely characterized in patients exposed to both classes.
Methods. Among patients with CLL/SLL at a single center exposed to both a cBTKi and venetoclax, we identified every subsequent line containing either class and recorded whether it was a within-class switch or rechallenge with a previously received agent, and the interval since the prior course. Continuation, bridging and cBTKi with a Richter-directed backbone were excluded. Outcome analyses take the first qualifying line per patient; switch tolerability is line-level (2 patients contributed 2 switches each). Responses were abstracted from clinician documentation using disease-appropriate criteria. The endpoint was time to next treatment or death (TTNT-D) from line start. Toxicity type was recorded only for lines discontinued for intolerance; therefore, only recurrence contributing to discontinuation of the second agent was ascertainable. Data cutoff 30 June 2026. Analyses are descriptive and non-comparative.
Results. Of 167 patients, 42 were double-refractory (DR: progression on both) and 125 double-exposed (DE); median age 69, with 5 prior lines in DR and 4 in DE. Across 152 sequentially treated patients the cBTKi was stopped for intolerance in 66 (43%) and progression in 59 (39%), venetoclax for progression in 51 (34%), planned completion in 38 (25%) and intolerance in 34 (22%). Among 110 cBTKi (76) and venetoclax (34) lines stopped for intolerance (a line could carry >1 toxicity), common AEs were cardiac events (28%), bleeding (25%) and arthralgia (13%) with cBTKi, and cytopenias (62%) and tumor lysis (12%) with venetoclax.
Among 23 within-class cBTKi switch lines after intolerance in 21 patients, mostly ibrutinib to acalabrutinib or zanubrutinib, 4 second-agent switches were discontinued for intolerance; the index toxicity contributed to 3 lines across 2 patients. The remaining 19 ended for progression (12), planned completion (3) or regimen change while responding (2), or remained ongoing (3). Because the toxicity type was unavailable unless the second agent was stopped for intolerance, the absence of recurrence cannot be inferred.
Twenty-eight patients contributed to the patient-level cBTKi outcome analysis; 10 also contributed to the switch analysis. In DE, treatment was predominantly a within-class switch (15/20), initiated a median of 39 months after the prior course, with a median TTNT-D of 23.7 months (95% CI, 6.1-NE) and responses in 5/18 evaluable patients (28%; 95% CI, 10-53). In DR, all 8 had previously progressed on a cBTKi; none of the 6 receiving the same-agent rechallenge after a median interval of 2.7 months responded, whereas 1/2 receiving a within-class switch responded. Median TTNT-D was 2.2 months (95% CI, 1.4-NE). Histologic transformation occurred at or after landmark in 7 DR and 6 DE patients, with a 36-month cumulative incidence of 18% and 7% respectively (death as competing risk).
Nineteen patients were retreated with venetoclax, and outcome varied by why their previous venetoclax course had ended. Retreatment after a planned fixed-duration course (n=3, all combinations) gave 3/3 responses with 2 CR and a median TTNT-D of 37.2 months, versus 4.4 months after prior progression in DE (n=4), 1.5 months after prior intolerance (n=2), and 2.5 months in DR (n=7, 2/7 responses). Separately, retreatment was combination-based in 13 patients and single-agent in 6, with responses in 10/13 and 1/6, respectively.
Conclusions. Among patients exposed to both classes, switching to a different cBTKi after intolerance was rarely limited by toxicity. In DE, cBTKi re-exposure after a prolonged interval was associated with prolonged disease control. Venetoclax retreatment appeared most active after planned completion, though the regimen is confounded with disease state. In contrast, the same agent rechallenge shortly after progression in DR produced minimal responses. These findings support within-class switching after intolerance and selective venetoclax retreatment after planned completion, and give little evidence of benefit from same-agent rechallenge in DR.
DISCLOSURES
Yumeng Zhang, MD: Curio Science - Honoraria; Plexus Communications - Honoraria; Acrotech Biopharma - Consultancy (Includes expert testimony); Citius Oncology - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Arima Genomics - Consultancy (Includes expert testimony); Kyowa Hakko Kirin Pharma, Inc. - Consultancy (Includes expert testimony); AbbVie, Inc. - Consultancy (Includes expert testimony)